C Gridelli
Overview
Explore the profile of C Gridelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
1655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arenare L, Di Liello R, De Placido P, Gridelli C, Morabito A, Pignata S, et al.
ESMO Open
. 2024 Dec;
9(11):103693.
PMID: 39617531
No abstract available.
2.
Arenare L, Di Liello R, De Placido P, Gridelli C, Morabito A, Pignata S, et al.
ESMO Open
. 2024 Mar;
9(3):102941.
PMID: 38452437
Background: Oncologists tend to under-report subjective symptoms during cancer treatment. This study describes the under-reporting rate of selected symptoms and explores its association with overall survival (OS). A secondary aim...
3.
Gridelli C, Peters S, Velcheti V, Attili I, de Marinis F
ESMO Open
. 2023 Mar;
8(2):101192.
PMID: 36965261
Background: The use of immune checkpoint inhibitors (ICIs) in the front-line treatment of advanced non-small-cell lung cancer (NSCLC) is currently the standard of care. However, as clinical trials include a...
4.
Gridelli C, Peters S, Mok T, Forde P, Reck M, Attili I, et al.
ESMO Open
. 2021 Dec;
7(1):100355.
PMID: 34922299
Background: Immunotherapy represents the standard of care in the first-line treatment of advanced non-small-cell lung cancer (NSCLC), either as monotherapy in high programmed death-ligand 1 (PD-L1)-positive tumors (≥50%) or in...
5.
Spagnuolo A, Palazzolo G, Sementa C, Gridelli C
Expert Opin Pharmacother
. 2020 Jan;
21(4):491-506.
PMID: 31957503
: Angiogenesis is the process by which the tumor develops its potential for growth and distant metastasis. The main proangiogenic switch is vascular endothelial growth factor (VEGF), which, along with...
6.
Perrone F, Jommi C, Di Maio M, Gimigliano A, Gridelli C, Pignata S, et al.
Ann Oncol
. 2016 Oct;
27(12):2224-2229.
PMID: 27789469
Background: Cancer may cause financial difficulties, but its impact in countries with public health systems is unknown. We evaluated the association of financial difficulties with clinical outcomes of cancer patients...
7.
Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C
Expert Rev Clin Pharmacol
. 2016 Sep;
9(12):1571-1581.
PMID: 27623999
Lung cancers remain the principal cause of death cancer-related worldwide with a poor survival rate at five years from diagnosis. In patients with NSCLC harboring specific genetic alterations the anti...
8.
Vansteenkiste J, Barlesi F, Waller C, Bennouna J, Gridelli C, Goekkurt E, et al.
Ann Oncol
. 2015 May;
26(8):1734-40.
PMID: 25939894
Background: This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with...
9.
Scagliotti G, Gridelli C, de Marinis F, Thomas M, Dediu M, Pujol J, et al.
Lung Cancer
. 2014 Aug;
85(3):408-14.
PMID: 25088661
Objectives: Two phase III trials of advanced NSCLC patients were compared to examine relative efficacy and safety of differing treatment regimens. The JMDB trial investigated first-line pemetrexed-cisplatin (pemetrexed 500mg/m(2) plus...
10.
Pallis A, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G, Jaklitsch M, et al.
Ann Oncol
. 2014 Mar;
25(7):1270-1283.
PMID: 24638905
Non-small-cell lung cancer (NSCLC) is a very common disease in the elderly population and its incidence in this particular population is expected to increase further, because of the ageing of...